Skip to content
value.today

Allevion Therapeutics, Inc.

🇺🇸 Irvine, California, USABiotechnologyFounded 2018
Total raised
$2 M
2 rounds on record
Latest round
$1 M
Mar 2024
First round on record
Jun 2021
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Allevion Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2024$1 MNo. 2Under $2 million

Allevion Therapeutics, Inc.: Raise no. 2, Mar 2024

Investors in this round

7 investors had bought by the notice of Mar 26, 2024: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$300,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Neal Hermanowicz · Executive Officer · Mr. Hermanowicz serves as an executive officer of the company.
  • Pintoo Shah · Executive Officer · Mr. Shah serves as an executive officer of the company.
  • Shahram Moaddeb · Executive Officer, Director, Promoter · Mr. Moaddeb is the founder, chairman of the board and chief executive officer of the company.
  • Dan Dearen · Director · Mr. Dearen serves a director of the company.
  • Jack Wang · Director · Mr. Wang serves as a director of the company.
  • Mahmood Razavi · Director · Mr. Razavi serves as a director of the company.
  • Randy Werneth · Director · Mr. Werneth serves as a director of the company.
  • Roy Tanaka · Director · Mr. Tanaka serves as a director of the company.
  • Shinya Miike · Director · Mr. Miike serves as a director of the company.

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Up to approximately $300,000 of the proceeds of the offering may be used to reimburse officers for out-of-pocket expenses incurred in connection with the offering and to pay officer salaries.”

Signed by Shahram Moaddeb, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 26, 2024. Read the notice at the SEC.

equitySEC
Jun 2021$1 MNo. 1Under $2 million

Allevion Therapeutics, Inc.: Raise no. 1, Jun 2021

Investors in this round

1 investor had bought by the notice of Jul 14, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$1,000,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$200,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Neal Hermanowicz · Executive Officer · Mr. Hermanowicz serves as a executive officer of the company.
  • Pintoo Shah · Executive Officer · Mr. Shah serves as an executive officer of the company.
  • Shahram Moaddeb · Executive Officer, Director, Promoter · Mr. Moaddeb is the founder, chairman of the board and chief executive officer of the company.
  • Dan Dearen · Director · Mr. Dearen serves a director of the company.
  • Jack Wang · Director · Mr. Wang serves as a director of the company.
  • Mahmood Razavi · Director · Mr. Razavi serves as a diector of the company.
  • Randy Werneth · Director · Mr. Werneth serves as a director of the company.
  • Roy Tanaka · Director · Mr. Tanaka serves as a director of the company.

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Up to approximately $200,000 of the proceeds of the offering may be used to reimburse officers for out-of-pocket expenses incurred in connection with the offering and to pay officer salaries.”

Signed by Shahram Moaddeb, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 14, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Allevion Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2024).

    SEC Form D · Mar 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2024

That is all the official record says: Allevion Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Allevion Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 7 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Allevion Therapeutics, Inc.
NameRoleNamed in
Neal HermanowiczMr. Hermanowicz serves as an executive officer of the company.Mar 2024
Pintoo ShahMr. Shah serves as an executive officer of the company.Mar 2024
Shahram MoaddebMr. Moaddeb is the founder, chairman of the board and chief executive officer of the company.Mar 2024
Dan DearenMr. Dearen serves a director of the company.Mar 2024
Jack WangMr. Wang serves as a director of the company.Mar 2024
Mahmood RazaviMr. Razavi serves as a director of the company.Mar 2024
Randy WernethMr. Werneth serves as a director of the company.Mar 2024
Roy TanakaMr. Tanaka serves as a director of the company.Mar 2024
Shahram MoaddebMr. Moaddeb is the founder, chairman of the board and chief executive officer of the company.Mar 2024
Shinya MiikeMr. Miike serves as a director of the company.Mar 2024
Shahram MoaddebMr. Moaddeb is the founder, chairman of the board and chief executive officer of the company.Mar 2024